UNSPSC 51321503: Alirocumab

Alirocumab is a PCSK9 inhibitor used as an adjunct to manage heterozygous familial hypercholesterolemia or clinical atherosclerotic cardiovascular disease in patients who require additional lowering of LDL-cholesterol (LDL-C)

UNSPSC 51321503 Alirocumab, a Commodity code, shows minimal recent state and local procurement activity aligned with its pharmaceutical scope. The recent opportunities posted under this code do not represent purchases of alirocumab or similar PCSK9 inhibitor biologics; instead, they reflect misclassification or tangential pharmaceutical-related solicitations. Most recorded postings are networking events, vendor forums, and informational sessions rather than product procurements—Marion County's Reverse Trade Show, Williamson County's Vendor Forum, Indian River County's Vendor Open House, Collin County's Purchasing Professionals Meet & Greet, the Central Florida NIGP Reverse Trade Show, Pasco County's How to Do Business Event, and the FAPPO Annual Tradeshow. Of the solicitations with actual deliverables, Seminole County, Florida issued an IFB for Naloxone and Safe Drug Deactivation Systems (posted June 30, 2026, response due July 26, 2023—a date inconsistency in the source), and the City of Tucson Fire Department issued an RFP for BLS/ALS pharmaceuticals and supplies plus VendNovation vending machines (posted June 24, 2026). Neither of these represents procurement of alirocumab. The Pinellas County forensic laboratory ITQ for drug standards and the MMCAP cooperative RFP for generic multi-source pharmaceuticals and OTC products are similarly unrelated to this biologic's clinical scope.

Activity is concentrated in Florida and Arizona, with secondary mentions of Texas, Minnesota, and Arkansas. The issuing bodies span county governments, municipalities, fire departments, and state cooperative purchasing entities. Because the recent opportunities tagged to this code do not reflect actual demand for alirocumab—a specialty injectable cardiovascular medication—the code signals low or misdirected procurement interest at the state and local level. Firms pursuing alirocumab or similar biologic contracts should monitor disease-management and pharmacy benefit programs operated by state Medicaid agencies, county health departments, and integrated delivery systems rather than rely on this code's current activity stream.